Cynata Therapeutics Limited (FRA:51S)

Germany · Delayed Price · Currency is EUR

0.137

+0.010 (7.87%)

At close: Dec 4, 2025

15.13% (1Y)

Market Cap	36.55M
Revenue (ttm)	1.05M
Net Income (ttm)	-5.24M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.137
Previous Close	0.127
Day's Range	0.137 - 0.137
52-Week Range	0.062 - 0.174
Beta	n/a
RSI	53.61
Earnings Date	Nov 27, 2025

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a n... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2003

Employees 2

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 51S

Full Company Profile

Financial Performance

In 2025, Cynata Therapeutics's revenue was 1.89 million, a decrease of -18.59% compared to the previous year's 2.32 million. Losses were -9.39 million, -3.63% less than in 2024.

Financial numbers in AUD Financial Statements

News

There is no news available yet.